Shanghai Runda Medical Technology Toekomstige groei

Future criteriumcontroles 3/6

Shanghai Runda Medical Technology zal naar verwachting dalen met 94.6% per jaar. De winst per aandeel zal naar verwachting groeien met 95.3% per jaar.

Belangrijke informatie

94.6%

Groei van de winst

95.3%

Groei van de winst per aandeel

Life Sciences winstgroei	31.9%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	20 May 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Earnings Tell The Story For Shanghai Runda Medical Technology Co., Ltd. (SHSE:603108) As Its Stock Soars 39%

Oct 22

These 4 Measures Indicate That Shanghai Runda Medical Technology (SHSE:603108) Is Using Debt Extensively

Oct 18

Shanghai Runda Medical Technology (SHSE:603108) Has A Somewhat Strained Balance Sheet

Jun 26

Shanghai Runda Medical Technology Co., Ltd.'s (SHSE:603108) Earnings Haven't Escaped The Attention Of Investors

Jun 04

Does Shanghai Runda Medical Technology (SHSE:603108) Deserve A Spot On Your Watchlist?

Mar 21

Shanghai Runda Medical Technology Co., Ltd. (SHSE:603108) Stock Rockets 31% But Many Are Still Ignoring The Company

Mar 04

These 4 Measures Indicate That Shanghai Runda Medical Technology (SHSE:603108) Is Using Debt Extensively

Feb 27

Winst- en omzetgroeiprognoses

SHSE:603108 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
9/30/2024	8,433	40	455	754	N/A
6/30/2024	8,761	190	513	802	N/A
3/31/2024	9,042	215	525	819	N/A
12/31/2023	9,147	273	410	730	N/A
9/30/2023	9,751	395	191	452	N/A
6/30/2023	10,255	433	-411	-139	N/A
3/31/2023	10,504	457	-499	-225	N/A
12/31/2022	10,494	418	-701	-429	N/A
9/30/2022	9,854	365	-577	-266	N/A
6/30/2022	9,378	336	-172	155	N/A
3/31/2022	9,008	332	-61	240	N/A
12/31/2021	8,860	380	70	371	N/A
9/30/2021	8,784	416	-236	122	N/A
6/30/2021	8,369	422	-123	244	N/A
3/31/2021	7,790	388	34	398	N/A
12/31/2020	7,069	330	-8	323	N/A
9/30/2020	6,784	253	-23	249	N/A
6/30/2020	6,700	246	-86	162	N/A
3/31/2020	6,820	273	-333	-61	N/A
12/31/2019	7,052	310	-42	247	N/A
9/30/2019	6,821	311	170	452	N/A
6/30/2019	6,464	292	204	481	N/A
3/31/2019	6,200	273	323	574	N/A
12/31/2018	5,964	262	274	539	N/A
9/30/2018	5,729	295	38	288	N/A
6/30/2018	5,351	267	N/A	167	N/A
3/31/2018	4,855	242	N/A	-6	N/A
12/31/2017	4,319	219	N/A	-88	N/A
9/30/2017	3,642	199	N/A	-169	N/A
6/30/2017	3,029	164	N/A	-152	N/A
3/31/2017	2,516	134	N/A	-171	N/A
12/31/2016	2,165	116	N/A	-125	N/A
9/30/2016	1,948	115	N/A	-96	N/A
6/30/2016	1,812	105	N/A	-228	N/A
3/31/2016	1,721	95	N/A	-205	N/A
12/31/2015	1,629	92	N/A	-227	N/A
9/30/2015	1,528	92	N/A	-101	N/A
6/30/2015	1,483	84	N/A	-22	N/A
3/31/2015	1,420	81	N/A	112	N/A
12/31/2014	1,359	75	N/A	36	N/A
12/31/2013	1,026	68	N/A	32	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 603108 ( 94.6% per jaar) ligt boven de spaarquote ( 2.8% ).

Winst versus markt: De winst van 603108 ( 94.6% per jaar) zal naar verwachting sneller groeien dan de CN markt ( 26.3% per jaar).

Hoge groeiwinsten: De winst van 603108 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van 603108 naar verwachting sneller zal groeien dan de markt CN.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van 603108 naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van 603108 naar verwachting over 3 jaar hoog zal zijn

Shanghai Runda Medical Technology Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Third quarter 2024 earnings released: CN¥0.061 loss per share (vs CN¥0.19 profit in 3Q 2023)

Earnings Tell The Story For Shanghai Runda Medical Technology Co., Ltd. (SHSE:603108) As Its Stock Soars 39%

These 4 Measures Indicate That Shanghai Runda Medical Technology (SHSE:603108) Is Using Debt Extensively

New minor risk - Share price stability

Shanghai Runda Medical Technology Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 28%

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.16 in 2Q 2023)

Shanghai Runda Medical Technology Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Shanghai Runda Medical Technology (SHSE:603108) Has A Somewhat Strained Balance Sheet

Shanghai Runda Medical Technology Co., Ltd.'s (SHSE:603108) Earnings Haven't Escaped The Attention Of Investors

Shanghai Runda Medical Technology Co., Ltd., Annual General Meeting, May 23, 2024

Shanghai Runda Medical Technology Co., Ltd., Annual General Meeting, May 23, 2024

Shanghai Runda Medical Technology Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Does Shanghai Runda Medical Technology (SHSE:603108) Deserve A Spot On Your Watchlist?

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 15%

Shanghai Runda Medical Technology Co., Ltd. (SHSE:603108) Stock Rockets 31% But Many Are Still Ignoring The Company

These 4 Measures Indicate That Shanghai Runda Medical Technology (SHSE:603108) Is Using Debt Extensively

Investor sentiment deteriorates as stock falls 16%

New minor risk - Shareholder dilution

Shanghai Runda Medical Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Investor sentiment improves as stock rises 23%

Third quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.25 in 3Q 2022)

Investor sentiment improves as stock rises 17%

Shanghai Runda Medical Technology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.21 in 2Q 2022)

New minor risk - Dividend sustainability

Investor sentiment deteriorates as stock falls 23%

New major risk - Share price stability

Shanghai Runda Medical Technology Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment improves as stock rises 35%

Investor sentiment improves as stock rises 17%

Full year 2022 earnings released: EPS: CN¥0.72 (vs CN¥0.66 in FY 2021)

Investor sentiment improves as stock rises 24%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.20 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.20 in 2Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥0.66 (vs CN¥0.57 in FY 2020)

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.21 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.15 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.05 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.57 (vs CN¥0.53 in FY 2019)

New 90-day low: CN¥10.36

New 90-day low: CN¥10.56

Investor sentiment improved over the past week

New 90-day low: CN¥11.50

New 90-day low: CN¥12.80

Third quarter earnings released

First half earnings released

New 90-day high - CN¥15.85

Shanghai Runda Medical Technology Co., Ltd. to Report Q2, 2020 Results on Aug 28, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven